| Literature DB >> 26644203 |
J E Megías-Vericat1,2, M J Herrero1,3, L Rojas1,4, P Montesinos5, V Bosó1,2, F Moscardó5, D Martínez-Cuadrón5, J L Poveda2, M Á Sanz5, S F Aliño1,3,6.
Abstract
The polymorphism rs16754 of the WT1 gene has been described as a possible prognostic marker in different acute myeloid leukemia (AML) cohorts; however, it is not supported by all the studies. We performed the first meta-analysis evaluating the effect of this polymorphism upon the effectiveness of standard AML therapy. Fourteen cohort studies were included (3618 patients). Patients with the variant allele showed a significant higher overall survival (OS) at 5 years (OR:1.24, 95% CI: 1.06-1.45, P=0.007, with dominant model). WT1 did not influence complete remission, but a higher disease-free survival was observed with the variant allele. In the subgroup analysis, Caucasians, pediatric and patients treated with idarubicin and etoposide carrying the variant allele showed consistent results in OS, whereas patients with cytogenetically normal AML did not show differences. To verify the effect of this polymorphism upon other outcomes, studies in larger and multiracial populations are needed.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26644203 DOI： 10.1038/tpj.2015.80
Source DB: PubMed Journal: Pharmacogenomics J ISSN： 1470-269X Impact factor: 3.550